Tauriga Sciences Inc. to Form Wholly Owned Subsidiary Focused on the Development, Marketing and Distribution of Products that Target Muscle Tension
The Company plans to complete the formation of this new wholly owned subsidiary within the next 30 days and will keep shareholders informed of progress. The subsidiary will be called ColluMauxil Therapeutics LLC (“ColluMauxil”), which is based on the Latin terms for neck relief — “collum” and “auxilium.” The Company has already contracted the services of New Jersey based PrintComm to establish the graphics and logo associated with ColluMauxil.
Tauriga plans to develop, market, distribute and potentially license a broad array of products and technologies that may help individuals who are affected by muscle tension. The Company has already identified potential products and technologies of interest and is actively working towards the goal of creating an innovative product line to launch the business activities of ColluMauxil. The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments.
Additionally, the Company plans on developing a product that specifically targets muscle tension in the neck, shoulder, and upper back. The Company envisions that this product will incorporate a roll-on delivery system (“Roll-On Product”) which is easier to apply to a specific area on the body. The Company also plans to develop a Roll-On Product that incorporates CBD Oil (“Cannabis Oil”), which is a legal alternative to THC oil, and it is available for sale in all states as well as around the world. Cannabis Oil is widely believed to provide relief to individuals who suffer from muscle tension, tenderness, and pain. Both contemplated Roll-On Products will be branded under the ColluMauxil name.
However, until these contemplated products are completed and distributed to the retail market, there can be no guaranty that any revenue will ever be generated. The Company believes it can raise the necessary funds to develop and begin distribution of its first muscles tension product for approximately $200,000, which it hopes to obtain through equity financing (“private placement”). The Company is confident that it will regain fully reporting status during the current quarter, which enables it to rely on Rule 144 for financing activities. The Company believes none of the contemplated products to be developed under the ColluMauxil brand will require approval from the Food and Drug Administration.
When the body is stressed, muscles tense up. Muscle tension is almost a reflex reaction to stress — the body’s way of guarding against injury and pain. With sudden onset stress, the muscles tense up all at once, and then release their tension when the stress passes. Chronic stress causes the muscles in the body to be in a more or less constant state of guardedness. When muscles are taut and tense for long periods of time, this may trigger other reactions of the body and even promote stress-related disorders. For example, both tension-type headache and migraine headache are associated with chronic muscle tension in the area of the shoulders, neck and head. Millions of Americans suffer from chronic painful conditions secondary to musculoskeletal disorders.
Tauriga’s Chief Executive Officer, Seth M. Shaw, expressed, “The Company and its management have worked hard to establish a business model that leverages the Company’s strengths and valuable relationships. The formation of ColluMauxil enables the Company to focus on launching a multi-faceted business model that has the potential to both restore and create shareholder value. As someone who has personally suffered from both chronic muscle tension and tension migraines, I fully understand how painful and debilitating this type of condition can be. The Company will focus on introducing and marketing innovative products and technologies with the equally important goals of generating profitable revenue and helping individuals in the process.”
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com